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Virtually all US military basic trainees receive season-
al influenza vaccine. Surveillance data collected from
December 2005 through March 2006 were evaluated to
estimate effectiveness of the influenza vaccine at 6 US mil-
itary basic training centers. Vaccine effectiveness against
laboratory-confirmed influenza was 92% (95% confidence
interval 85%–96%).
P
ublic health concerns over the potential for a devastat-
ing influenza pandemic in the near future are well
known. Surveillance efforts have increased throughout the
world, and much time and money have been directed
toward preparedness for such a pandemic. Given that vac-
cination rates vary greatly among the nonmilitary popula-
tion and that influenza diagnostics are sporadically
available, annual influenza vaccine effectiveness studies
based on laboratory-confirmed diagnoses are rare.
However, evidence of locally circulating strains evading
the vaccine-induced protection could be critical for early
recognition and intervention. In addition, the emergence of
pandemic strains within military populations has been
noted. The first documented influenza outbreak in the
spring of 1918, before the great influenza pandemic of
1918–19, was among recruits at Fort Riley, Kansas (1). In
1976, a unique strain of influenza (H1N1) caused an out-
break at Fort Dix, New Jersey, causing 1 death, and creat-
ing concern over spread of this nonvaccine strain (2).
Highly vaccinated military populations, under close sur-
veillance, provide the opportunity for annual calculation of
influenza vaccine effectiveness, thereby benefiting global
pandemic preparedness.
The Study
The Naval Health Research Center (NHRC) began
conducting tri-service surveillance for febrile respiratory
illness at military training centers in 1996; by 1999, this
surveillance network had expanded to include 8 of the
largest military basic training centers in the United States
(3). This surveillance includes the systematic collection of
throat swab specimens and clinical data (including but not
limited to gender, date of birth, symptoms, influenza vac-
cination status, type of vaccine received, and date of vac-
cination) from consenting US military trainees meeting the
case definition for febrile respiratory illness (oral tempera-
ture >100.5°F [38.0°C] and a cough or sore throat).
Samples are stored locally at each site at −70°C until they
are forwarded to the Naval Respiratory Disease
Laboratory at NHRC for viral culture and molecular diag-
nostic processing. Research personnel at participating sur-
veillance sites report the weekly number of trainees who
sought care for febrile respiratory illness and total trainee
populations for their respective sites, and rates for such ill-
nesses are calculated.
During the 2003–04 influenza season, we recognized
the opportunity of using data from this ongoing active sur-
veillance to estimate influenza vaccine effectiveness in
protecting against both laboratory-confirmed influenza
and febrile respiratory illness of any cause among US mil-
itary basic trainees. Despite concerns that vaccine effec-
tiveness during the 2003–04 season would be low because
of the poor match between the components of the vaccine
and the circulating strain (4), the vaccine provided good
protection (94.4%) against laboratory-confirmed influenza
that season (5). Annual vaccine effectiveness calculations
are important as we heighten our preparedness for pan-
demic influenza strains; therefore, we performed similar
calculations for the 2004–05 and 2005–06 seasons.
During the late fall and winter seasons, all active-duty
military forces are required to receive the influenza vac-
cine, and this policy is strictly enforced in training camps.
Upon arrival, all incoming trainees receive mandatory
influenza vaccination, either the trivalent inactivated
influenza vaccine by injection (FluZone, Sanofi Pasteur,
Lyon, France) or intranasal cold-adapted, live, attenuated
influenza vaccine (CA-LAIV) spray (FluMist,
MedImmune, Gaithersburg, MD, USA).
For this analysis, vaccine protection was assumed to
begin 14 days postvaccination. Therefore, in an 8-week
training program, 25% of trainees were considered
“unvaccinated” at any given time, assuming immunity
takes 14 days to develop. Likewise, 33% of trainees in a 6-
week training program were considered unprotected by the
vaccine at any time. These assumptions allow estimates of
denominator data for “vaccinated” and “unvaccinated”
person-weeks in calculations of vaccine effectiveness.
From January through March 2006 all new trainees
arriving for basic training received the influenza vaccine;
all recruits already present had been vaccinated. The
observation period for this analysis included January
1–March 31, 2006. However, 2 sites, Naval Service
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Recruit Depot, San Diego, had completed vaccination by
December 2005. Therefore, December was included in the
observation period for those sites as well. Total person-
weeks in recruit training during the observation period
were obtained directly from the participating training cen-
ters. Vaccine effectiveness was calculated for both labora-
tory-confirmed influenza and any cause of febrile
respiratory illness as follows: 100 × (1 – relative risk = 1 –
[rate in vaccinated group]/[rate in unvaccinated group]).
During the observation period, 6 of 8 surveillance
sites had influenza activity and were included in this analy-
sis. In 479,181 person-weeks of observation, 4,052 cases
of febrile respiratory illness were reported from these 6
sites, and 722 patients were enrolled into the surveillance
study (includes throat swab specimen, case data, and con-
sent). Seventy (9.7%) specimens tested positive for
influenza, by either culture or molecular techniques.
Rates of laboratory-confirmed influenza were higher
among unvaccinated trainees at all sites except Fort
Benning, Georgia, which had only 3 cases (Figure).
Overall, influenza vaccine effectiveness among US mili-
tary trainees was 92% (confidence interval [CI]
85.4–95.6%) during the 2005–06 season (Table). Vaccine
effectiveness against laboratory-confirmed influenza was
high (range 86%–94%) in each of the past 3 seasons.
Vaccine effectiveness against non–laboratory-confirmed
febrile respiratory illness was lower, ranging from −10% in
2005–06 to 52% in 2004–05.
Conclusions
This analysis suggests that the 2005–06 influenza vac-
cine was highly effective in protecting US military basic
trainees against laboratory-confirmed influenza. Further-
more, these data suggest that both the trivalent inactivated
vaccine injection and the CA-LAIV intranasal spray were
equally effective, because the Marine Corps Recruit Depot
in San Diego vaccinated its trainees with CA-LAIV almost
exclusively, and vaccine effectiveness at that site was 95%
(vaccine effectiveness at all other sites combined = 90%).
These estimates of effectiveness were supported by
results of additional analyses that would be expected to
bias the outcome toward the null hypothesis. For example,
a 7-day lag period before immune response was considered
in an alternative analysis, and it yielded similar results: the
calculated vaccine effectiveness changed only slightly,
from 92% to 90%. We also analyzed vaccine effectiveness,
assuming that 10% fewer trainees were vaccinated at any
given point, yet the calculated vaccine effectiveness was
only reduced to 87%.
In contrast to the consistently high effectiveness of
the vaccines against laboratory-confirmed influenza, the
effectiveness against febrile respiratory illness of any
cause was much lower and varied with each season
(13.9% in 2003–04, 52.1% in 2004–05, and −10% in
2005–06). This lower effectiveness in 2005–06 is most
likely due to the generally high proportion of adenovirus
infection seen in this population (6), and the lesser effec-
tiveness is further exacerbated by the tendency for aden-
oviral infections to occur beyond the second week of
training. The lower vaccine effectiveness seen against
febrile respiratory illness of any cause gives credence to
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Figure. Incidence of laboratory-confirmed influenza by vaccination
status. AFB, Air Force Base; NSTC, Naval Service Training
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the estimates of high vaccine effectiveness against labora-
tory-confirmed influenza. If a measurement bias existed,
both estimates would be affected.
As a highly vaccinated population, military personnel,
and basic trainees in particular, can provide critical infor-
mation regarding the effectiveness of each year’s influen-
za vaccine formulations. Because of the annual variations
of both the vaccine formulations and the circulating
strains, influenza vaccine effectiveness should be evaluat-
ed annually. With the ever-rising concerns of an imminent
influenza pandemic, reliable and rigorous influenza sur-
veillance is paramount. Our existing surveillance network
will allow us to repeat the methods used in this analysis
each year, thus providing valuable estimates of influenza
vaccine effectiveness to the public health community.
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